NGM Biopharmaceuticals reports Q4 EPS (45c), consensus (51c)

Reports Q revenue $18.2M, consensus $6.76M. Cash, cash equivalents and short-term marketable securities were $271.5M as of December 31 , compared to $366.3M as of December 31, 2021."In 2022, NGM Bio further focused our clinical development efforts on our portfolio of clinical-stage solid tumor oncology programs, while continuing the efforts of our prolific drug discovery engine to produce potential next-generation biologic therapeutics." said David J. Woodhouse, Ph.D., Chief Executive Officer at NGM Bio. "At year end, we reported promising preliminary data from our first myeloid checkpoint inhibitor program, NGM707, at the ESMO Immuno-Oncology Congress and advanced our other myeloid checkpoint inhibitor programs, NGM438 and NGM831, in their ongoing Phase 1/1b trials in patients with advanced solid tumors."